Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
About this item
Full title
Author / Creator
COMET-ICE Investigators , Gupta, Anil , Gonzalez-Rojas, Yaneicy , Juarez, Erick , Crespo Casal, Manuel , Moya, Jaynier , Falci, Diego R , Sarkis, Elias , Solis, Joel , Zheng, Hanzhe , Scott, Nicola , Cathcart, Andrea L , Hebner, Christy M , Sager, Jennifer , Mogalian, Erik , Tipple, Craig , Peppercorn, Amanda , Alexander, Elizabeth , Pang, Phillip S , Free, Almena , Brinson, Cynthia , Aldinger, Melissa and Shapiro, Adrienne E
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this ongoing, randomized, phase 3 trial, sotrovimab (a SARS-CoV-2–targeted monoclonal antibody) or placebo was administered to outpatients within 5 days after the onset of Covid-19 symptoms. The incidence of hospitalization for any cause or death was lower among patients who received sotrovimab (1% vs. 7%).
Alternative Titles
Full title
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
Authors, Artists and Contributors
Author / Creator
Gupta, Anil
Gonzalez-Rojas, Yaneicy
Juarez, Erick
Crespo Casal, Manuel
Moya, Jaynier
Falci, Diego R
Sarkis, Elias
Solis, Joel
Zheng, Hanzhe
Scott, Nicola
Cathcart, Andrea L
Hebner, Christy M
Sager, Jennifer
Mogalian, Erik
Tipple, Craig
Peppercorn, Amanda
Alexander, Elizabeth
Pang, Phillip S
Free, Almena
Brinson, Cynthia
Aldinger, Melissa
Shapiro, Adrienne E
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2587752627
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2587752627
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2107934
